

ASX Announcement

24 September 2019



- 1. Video Available Discussing Background and Structure of Eisai Licensing Agreement to Launch Cogstate Technology in Japan**
- 2. Eisai Provide Statement Regarding Continued Commitment to a Complete Dementia Ecosystem, Including Cogstate Partnership**

Cogstate (ASX.CGS) has today made available a video interview with Eisai Chief Strategy Officer, Kazumasa Nagayama, where Mr Nagayama and Cogstate CEO, Brad O'Connor, discuss the background and the structure of the agreement entered into between Cogstate and Eisai to launch Cogstate technology as a cognitive screening tool in Japan. The video can be accessed on the investor section of the Cogstate website at cogstate.com/investors.

In addition, Cogstate would like to bring to the attention of investors an announcement by Eisai and Biogen on 13 September 2019. In that communication, Eisai and Biogen announced the decision to discontinue the Phase III clinical studies (MISSION AD1, AD2) on the investigational oral BACE (beta amyloid cleaving enzyme) inhibitor elenbecestat (development code: E2609) in patients with early Alzheimer's disease. Also in that announcement, Eisai stated that this determination does not impact the program of the anti-amyloid beta protofibril monoclonal antibody BAN2401, and the phase III Clarity AD trial of BAN2401 will continue.

In respect of the announcement regarding the discontinuation of the phase III clinical studies for elenbecestat, Mr Nagayama confirmed, "Eisai remain committed to the development of potential therapeutic agents to help Alzheimer's disease patients. In addition, Eisai remains committed to the development of a broader dementia ecosystem, which includes our partnership with Cogstate in Japan; and we are looking forward to the launch of the Cogstate technology in Japan in the near future."

For further information contact:

Brad O'Connor

Cogstate Chief Executive Officer

+613 9664 1300 or 0411 888 347

boconnor@cogstate.com

About Cogstate

Cogstate Ltd (ASX:CGS) is the neuroscience company optimising brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare. Cogstate technologies provide rapid, reliable and highly sensitive computerised cognitive tests across a growing list of domains and support electronic clinical outcome assessment (eCOA) solutions to replace costly and error-prone paper assessments with real-time data capture. The company's clinical trials solutions include quality assurance services for study endpoints that combine innovative operational approaches, advanced analytics and scientific consulting. For nearly 20 years, Cogstate has proudly supporting the leading-edge research needs of biopharmaceutical companies and academic institutions and the clinical care needs of physicians and patients around the world. For more information, please visit www.cogstate.com. Investors wishing to learn more about Cogstate's business model can view a series of investor videos at www.cogstate.com/investors.